Capricor Therapeutics Inc. | Mutual Funds
Mutual Funds that own Capricor Therapeutics Inc.
Vanguard Total Stock Market Index Fund
478,917
1.56%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
294,197
0.96%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
74,861
0.24%
0
0%
07/31/2018
iShares Micro Cap ETF
37,997
0.12%
0
0%
09/06/2018
Fidelity Spartan Total Market Index Fund
31,524
0.1%
0
0%
07/31/2018
Fidelity Nasdaq Composite Index
12,301
0.04%
0
0%
07/31/2018
Vanguard Balanced Index Fund
9,210
0.03%
0
0%
07/31/2018
Vanguard Total Stock Market Index Trust
5,170
0.02%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
4,572
0.02%
0
0%
09/06/2018
BlackRock Master Extended Market Index Series
1,665
0.01%
0
0%
01/31/2018
| Address |
8840 Wilshire Boulevard
Beverly Hills California 90211
United States
|
|
Employees
|
- |
| Website |
http://www.capricor.com |
| Updated |
07/08/2019 |
| Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on November 20, 2013 and is headquartered in Beverly Hills, CA. |
